Biochemical Peculiarities and Drug Targets in Cryptosporidium parvum: Lessons from other Coccidian Parasites
- 1 August 1999
- journal article
- review article
- Published by Elsevier in Parasitology Today
- Vol. 15 (8), 333-338
- https://doi.org/10.1016/s0169-4758(99)01474-x
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Ultrastructural analysis of the sporozoite of Cryptosporidium parvumMicrobiology, 1998
- Human Cryptosporidiosis: Epidemiology, Transmission, Clinical Disease, Treatment, and DiagnosisAdvances in Parasitology, 1998
- Glycolytic enzyme activities in Cryptosporidium parvum oocystsFEMS Microbiology Letters, 1997
- Biochemistry of the CoccidiaAdvances in Parasitology, 1997
- The use of a new viability assay to determine the susceptibility ofCryptosporidiumandEimeriasporozoites to respiratory inhibitors and extremes of pHFEMS Microbiology Letters, 1996
- Chemotherapy of human and animal coccidioses: state and perspectivesZeitschrift Fur Parasitenkunde-Parasitology Research, 1996
- Comparison of the phosphofructokinase and pyruvate kinase activities of Cryptosporidium parvum, Eimeria tenella and Toxoplasma gondiiMolecular and Biochemical Parasitology, 1996
- Efficacy of 101 antimicrobials and other agents on the development ofCryptosporidium parvum in vitroPathogens and Global Health, 1996
- Cryptosporidium and cryptosporidiosis in man and animalsInternational Journal for Parasitology, 1995
- Some phosphonic acid analogs as inhibitors of pyrophosphate-dependent phosphofructokinase, a novel target in Toxoplasma gondiiBiochemical Pharmacology, 1995